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Abstract
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most com-
mon neurodegenerative disorders in humans. Because a significant percentage
of patients have clinical and pathological features of both diseases, it has been
hypothesized that the patho-cascades of the two diseases overlap. Despite this
evidence, these two diseases are rarely studied in a joint manner. In this paper, we
utilize clinical, imaging, genetic, and biospecimen features to cluster AD and PD
patients into the same feature space. By training a machine learning classifier on
the combined feature space, we predict the disease stage of patients two years after
their baseline visits. We observed a considerable improvement in the prediction
accuracy of Parkinson’s dementia patients due to combined training on Alzheimer’s
and Parkinson’s patients, thereby affirming the claim that these two diseases can be
jointly studied.
1 Introduction
Alzheimer’s disease (AD) is an irreversible, progressive neurological disease that gradually deteri-
orates cognitive abilities [8]. It is characterized by progressive impairment in memory, judgment,
language, and orientation to physical surroundings. The primary pathological features of AD are
neuronal loss and the accumulation of extracellular plaques containing amyloid β (Aβ) and neurofib-
rillary tangles (NFT) containing tau. Parkinson’s disease (PD) is a similarly irreversible, progressive
neurological disease that impairs movement. PD manifests as a movement disorder and a distinct form
of cognitive impairment with typical pathological characteristics of the accumulation of α-synuclein
in multiple brain regions.
Though AD and PD are clinically distinct entities, one can find pathological associations between
them. For instance, Aβ, an important hallmark of AD pathology, has been reported to be present in
some PD patients [11], while there have been indications that Lewy body deposition exists even in
AD patients [3]. The association might also extend to genes such as APOE and MAPT genes which
have been reported to be linked to the presence of Aβ aggregates [16] and increased tau protein
expression.
An important application of the hypothesis of overlap between AD and PD has been studying cognitive
decline in PD patients. Previous works report association of lower levels of cerebrospinal fluid (CSF)
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amyloid β with cognitive decline in PD patients [18]. Also, many imaging-based measures have been
reported to be associated with cognitive performance in PD. A baseline AD pattern of brain atrophy,
quantified using the Spatial Pattern of Atrophy for Recognition of AD (SPARE-AD) score, predicted
long-term global cognitive decline in non-demented PD patients [21].
Despite the discovery of such correlations, AD and PD communities remain distinct. This motivates
an aggregated, data-driven study to explore correlation between the two diseases, which could
potentially lead to clearer understanding and possible development of therapeutic targets for both
ailments. The main contribution of this paper is combining multiple modalities of two different data
sets of ADNI and PPMI patients and consequently predicting the onset of Dementia in PD patients
using it. To the best of our knowledge, this is the first work exploiting the overlap of these two
diseases to improve prediction accuracy of dementia in PD patients.
2 Methodology
2.1 Problem Statement
The aim is to predict a given patient’s cognitive status (Normal CI/MCI/Dementia) after 24 months
using his/her baseline features. Due to high clinical importance of prediction of onset of Dementia in
PD patients, the primary goal is to improve on state-of-the-art methods for the same.
2.2 Data
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database was used to fetch multimodal data for
AD patients. ADNI-2 participants meeting the criteria for single-domain or multidomain amnestic
MCI were selected, as in prior work [12]. The availability of all desired features and diagnosis
after 24 months led to a total of 355 patients. Parkinson’s Progression Markers Initiative (PPMI)
database was used to fetch multimodal data for PD patients. Montreal Cognitive Assessment (MoCA)
scores [13] were used for assignment of Dementia labels for PD patients. MoCA is a widely used
screening assessment for detecting cognitive impairment [5] [7]. Based on the availability of MoCA
scores, and other required features, we were reduced to 142 patients.
2.3 Features
(a) (b)
Figure 1: a) Reduced Image feature space comprising of all patients (AD/PD) b) All feature overlap
between AD and PD patients
The following features were selected for the purpose of this classification task. These features have
been found to drive dementia prediction [2].
2.3.1 Imaging Features
FreeSurferV5.1 software [6], which can analyze and visualize MRIs, was used to obtain pre-processed
image features. This allowed us to map ADNI and PPMI patients into a unified image feature space.
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Principal Component Analysis (PCA) [14] was used to reduce the feature space to three dimensions,
as illustrated in Fig 1a. Alternative methods such as independent component analysis and t-sne did
not perform as well as PCA on this data. Note that each data point is labeled by its cognitive label
after 24 months in addition to its dataset of origin. We observe that data points in the ADNI and
PPMI datasets that share common cognitive statuses are in close proximity with one another.
2.3.2 Genetic Features
Apolipoprotein E4 (ApoE4), which is the largest known genetic risk factor for late-onset sporadic
AD in a variety of ethnic groups [4, 17] was chosen as the only genetic feature. ApoE4 has also been
shown to be associated with cognitive decline in Parkinson’s disease [1].
2.3.3 Biospecimen Features
For biospecimen features, cerebrospinal fluid (CSF) total tau, phosphorylated tau 181 protein (p-
tau181), and CSF Aβ42 levels were selected. Elevated CSF total tau and p-tau181 concentrations
have shown to be associated with neuro degenerative changes in early AD [20, 18, 22]. Each of
these biomarkers also have strong prognostic and diagnostic potential in early-stage PD [10]. CSF
alpha-synuclein levels were also considered as a potential feature but could not be used due to
unavailability of data for ADNI-2/GO participants [9].
One can observe significant overlaps between feature values of clustered ADNI and PPMI patients in
Fig 1b, suggesting potential for accurate predictions for both kinds of patients.
2.4 Classifier
Using the features at baseline (gender, three imaging features, ApoE4 genotype, and the three
biospecimen features), a Random Forest classifier (500 trees with max features parameter as 0.6)
was trained to predict a patient’s cognitive disease label two years after the baseline. Preliminary
testing showed Random Forest outperforming other commonly used classifiers such as logistic
regression, support vector machine, multi-layer perceptron etc. This corroborates with the fact that
Random forests are inherently suited for multi-class problems and work well in combination with
numerical, categorical features. Five-fold cross-validation, splitting the folds on AD and PD patients
independently, and recombining them for the training to avoid imbalances between the two diseases,
was used. Thus, each fold contained equal proportions of AD and PD patients.
3 Results
Table 1 summarizes the results for the aforementioned classifier, testing different train-test set
combinations. Note that even though we list accuracy as a performance parameter, it was not used as
a measure of comparison because it can misinterpret the performance when the sample has imbalanced
class probabilities [12].
Table 1: Summary of results
Training set Test set AUC-Dementia AUC-MCI AUC-CI Accuracy Precision Recall
ADNI+PPMI ADNI+PPMI 0.88 0.64 0.72 0.53 0.57 0.53
ADNI+PPMI PPMI 0.95 0.53 0.62 0.57 0.33 0.36
ADNI+PPMI ADNI 0.91 0.68 0.77 0.52 0.55 0.53
PPMI PPMI 0.61 0.42 0.65 0.48 0.27 0.32
ADNI ADNI 0.89 0.67 0.77 0.52 0.56 0.55
Fig 2 presents the Receiver Operating Curves (ROC) for three relevant testing scenarios in Table 1.
Class 0 represents Dementia, class 1 MCI and class 2 Normal-CI. Fig 2a provides the generalized
performance of our model, wherein we train on ADNI+PPMI and test on ADNI+PPMI. Fig 2b
provides the result most relevant to our use-case. One can observe 1.5X increase in AUC-Dementia
value when we train our model on a combined ADNI+PPMI set as compared to PPMI set. This shows
drastic gains in prediction of Dementia in Parkinson’s patients (PDD) when we used a combined
feature space.
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(a) (b) (c)
Figure 2: Receiver Operating Curves (ROC) for three testing scenarios - (a) Train on ADNI and
PPMI, Test on ADNI and PPMI, (b) Train on ADNI and PPMI, Test on PPMI, (c) Train on ADNI
and PPMI, Test on ADNI - where Class 0 represents Dementia, class 1 MCI and class 2 Normal-CI
(a) Feature importance (b) Feature space without APOEgenotype
(c) Feature space with APOE geno-
type
Fig 3a illustrates importance of each feature used in the classifier. PCA_1, PCA_2, PCA_3 encompass
image features. They have a combined importance of 46 %, which points to the necessity of imaging
features. Abeta-42 has an importance of 17.5 %, which when combined with Total-tau and p-Tau
give considerable significance to biospecimen modality.
Note that ApoE Genotype has a small contribution in prediction outcome, which is counter-intuitive
as it has been found to hold high importance when predicting Dementia. We performed exploratory
study to clarify this issue. Fig 3b shows patient feature space without ApoE Genotype while Fig 3c
shows feature space with ApoE Genotype. One can clearly observe that ApoE Genotype acts as a
discriminating feature when predicting future diagnosis. Fig 3c depicts formation of clusters when
using all mentioned features, while in Fig 3b data has lower visual segregation, which might make
classifier less effective. This observation linked with the fact that RF classifier feature importance is
not reliable in situations where potential predictor variables vary in their scale of measurement or
their number of categories [19], establishes ApoE as an important predictor variable.
Although there is a dearth of research in prediction of Dementia in PD patients (PDD), we were able
to use Berlyand et.al [2] as baseline for our task. They trained a Logistic Regression classifier on a
AD cohort of 210 patients to predict control vs Dementia patients. They, then, used the trained model
to predict control vs Dementia on a PD cohort of 75 patients with considerably lower performance.
Note that we differ in our experiments - (1) usage of raw image features processed through Freesurfer
and reduced through PCA, (2) usage of both AD and PD patients for training the model and (3)
prediction of Normal_CI/MCI/Dementia patients instead of Normal/Dementia patients. We use
(1) as it opens up our model to better extract information from images and does not impose bias
unlike SPARE-AD score. Using (2) exposes our model to a larger data set and (3) provides a more
fine-grained outcome.
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4 Conclusion
This paper makes an attempt at predicting the onset of dementia in patients, with special interest to
PD patients. This is a task of high clinical importance. We obtain promising results as compared
to the state of the art. We show that using AD patients along with PD patients to build a model to
predict the onset of dementia in PD patients is a promising future direction. This also reaffirms our
claim that dementia in PD and AD share the same pathology. We believe this can help open up new
avenues of research going forward.
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5 Appendix
Table 2: Statistical summary of patients with assigned labels.
Dataset Baseline Diagnosis Future Diagnosis Number of patients
ADNI
Normal CI Normal CI 131
Normal CI MCI 11
Normal CI Dementia 2
MCI MCI 144
MCI Dementia 48
Dementia Dementia 19
PPMI
Normal CI Normal CI 75
Normal CI MCI 35
Normal CI Dementia 4
MCI MCI 20
MCI Dementia 7
Dementia Dementia 1
Combined
Normal CI Normal CI 206
Normal CI MCI 46
Normal CI Dementia 6
MCI MCI 164
MCI Dementia 55
Dementia Dementia 29
Table 2 summarizes the composition of different types of progressing patients used in our prediction
task. Note that we are only concerned with disease progression; hence, we do not consider disease
reverter cases (patients who improve in disease condition).
The eligibility criteria of MCI were participants with minimental state examination (MMSE) scores
equal to or greater than 24, a clinical dementia rating of 0.5, subjective and objective memory loss,
normal activities of daily living, and the absence of other neuropsychiatric disorders, including
Alzheimer’s disease, at baseline [15].
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